



S1 Fig. Kaplan-Meier analyses of overall survival (A) and progression-free survival (B) of patients receiving RR-CHOP chemotherapy according to sex. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; RR-CHOP, intensified the first cycle of rituximab plus eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab.